Cordycepin, derived from fungi, shows promise in cancer therapy by inhibiting growth factor signaling pathways critical for ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

The scientists found that the absence of a protein called PKCλ/ι in prostate cancer cells enables EZH2 to drive aggressive growth, even with androgen receptor inhibitors present. PKCλ/ι normally ...